Company Further Strengthens Commitment to Neuroscience Research and Pharmacokinetics/Drug Metabolism Support for Growing Pipeline
THOUSAND OAKS, Calif., Oct 16, 2003 -- Amgen Inc. (Nasdaq: AMGN), the world´s largest biotechnology company, today
announced that H. Christian Fibiger, Ph.D., has been named Vice President and
Global Therapeutic Area Head for Neuroscience Research and that Paul G.
Pearson, Ph.D., has been appointed Vice President of Pharmacokinetics and Drug
Metabolism (PKDM). These two new vice presidents will support the continuing
growth of the company´s pipeline and its discovery of important new human
Dr. Fibiger comes to Amgen from Eli Lilly and Company, where he served as
Vice President, Neuroscience Discovery Research and Clinical Investigation,
and Vice President, Lilly Research Laboratories, Europe. Before joining
Amgen, Dr. Pearson was Executive Director, Preclinical Drug Metabolism at
Merck Research Laboratories.
"Dr. Fibiger possesses a rare combination of proven business leadership
capabilities and stellar scientific credentials," said Joseph P. Miletich,
M.D., Ph.D., Senior Vice President, Research and Preclinical Development. "As
a member of the company´s research leadership team, Dr. Fibiger will be
responsible for driving the next phase of Amgen´s global neuroscience research
strategy and efforts."
"We are expanding our commitment in neuroscience research because of
enormous unmet medical needs," said Dr. Miletich. "Dr. Fibiger will lead our
existing neuroscience research efforts in areas such as Parkinson´s disease,
as well as help us develop novel therapeutics for other serious illnesses."
Dr. Pearson will enhance Amgen´s efforts across PKDM, especially in early
stage drug discovery, where the identification of robust drug candidates is a
critical first step in the development process. "Dr. Pearson brings a rich
scientific and technical background combined with extensive experience in
preclinical drug development. He will provide Amgen with a new level of
leadership in this vital area," said Dr. Miletich.
At Eli Lilly, Dr. Fibiger led the company´s global discovery and
development activities in neuroscience and managed the company´s four European
discovery and development sites. Prior to joining Lilly in 1998, Dr. Fibiger
had a lengthy, distinguished career at the University of British Columbia that
spanned 28 years. He is the author or co-author of more than 400 scientific
publications, has been an associate editor of the Journal of Psychiatry and
Neuroscience since 1990, and was co-editor-in-chief of the
Neuropsychopharmacology journal from 1995-1998. He is active in a number of
professional organizations, including being a Fellow of the American College
of Neuropsychopharmacology and a member of the International Society of
Neurochemistry. He also served as a Member of Council in the American College
of Neuropsychopharmacology from 2001-2003. Dr. Fibiger is the recipient of
numerous awards and distinctions, including the Tanenbaum Distinguished
Scientist Award in Schizophrenia Research (1993) and the Janssen Prize for
Innovations in Neuropsychopharmacology Research (1996).
Dr. Fibiger holds a B.Sc. in Chemistry and Psychology from the University
of Victoria, British Columbia, Canada, and a Ph.D. in Psychopharmacology from
Princeton University, Princeton, N.J.
As Merck´s Executive Director of Preclinical Drug Metabolism, Dr. Pearson
was responsible for providing PKDM support for drug discovery and development
programs at the company´s two largest sites. He also managed all Preclinical
Drug Metabolism activities in support of drug development efforts. He served
as a member of Merck´s Safety Assessment Review Committee and Preclinical
Development Review Committee and other leadership teams dedicated to long-
range planning and drug development.
Dr. Pearson received a B.Sc. in Pharmacy and a Ph.D. in Mechanistic Drug
Metabolism and Toxicology from Aston University, Birmingham, England.
Amgen is a global biotechnology company that discovers, develops,
manufactures and markets important human therapeutics based on advances in
cellular and molecular biology.
This news release contains forward-looking statements that involve
significant risks and uncertainties, including those discussed below and
others that can be found in Amgen´s Form 10-K for the year ended December 31,
2002, and in Amgen´s periodic reports on Form 10-Q and Form 8-K. Amgen is
providing this information as of the date of this news release and does not
undertake any obligation to update any forward-looking statements contained in
this document as a result of new information, future events or otherwise.
No forward-looking statement can be guaranteed and actual results may
differ materially from those we project. Amgen´s results may be affected by
its ability to successfully market both new and existing products domestically
and internationally, sales growth of recently launched products, difficulties
or delays in manufacturing its products, and regulatory developments (domestic
or foreign) involving current and future products and manufacturing
In addition, sales of Amgen´s products are affected by reimbursement
policies imposed by third party payors, including governments, private
insurance plans and managed care providers, and may be affected by domestic
and international trends toward managed care and healthcare cost containment
as well as possible U.S. legislation affecting pharmaceutical pricing and
reimbursement. Government regulations and reimbursement policies may affect
the development, usage and pricing of Amgen´s products. Furthermore, Amgen´s
research, testing, pricing, marketing and other operations are subject to
extensive regulation by domestic and foreign government regulatory
authorities. Amgen or others could identify side effects or manufacturing
problems with its products after they are on the market. In addition, Amgen
competes with other companies with respect to some of its marketed products as
well as for the discovery and development of new products. Discovery or
identification of new product candidates cannot be guaranteed and movement
from concept to product is uncertain; consequently, there can be no guarantee
that any particular product candidate will be successful and become a
In addition, while Amgen routinely obtains patents for its products and
technology, the protection offered by its patents and patent applications may
be challenged, invalidated or circumvented by its competitors. Further, some
raw materials, medical devices and component parts for Amgen´s products are
supplied by sole third party suppliers.
The statements in this press release that are not historical facts are
forward-looking statements based on current expectations of future events that
involve risks and uncertainties including, without limitation, risks
associated with the inherent uncertainty of pharmaceutical research, product
development, manufacturing, and commercialization, and economic conditions,
including interest and currency exchange rate fluctuations, the impact of
competitive or generic products, product liability and other types of
lawsuits, the impact of legislative and regulatory compliance and obtaining
approvals, and patents, and other risks and uncertainties, including those
detailed from time to time in Wyeth´s periodic reports, including quarterly
reports on Form 10-Q and the Annual Report on Form 10-K, filed with the
Securities and Exchange Commission. Actual results may vary materially from
the forward-looking statements.
CONTACT: Amgen, Thousand Oaks
Media, (805) 447-9753
Investors, (805) 447-1060